Data Sources: COVID-19

*Last updated on October 12, 2020

 

A resource gathering relevant open data sources of research and development, intellectual property and pricing related to COVID-19. This page is work in progress and will be updated regularly.

Contribute to improve and update this page!

We particularly welcome suggestions on additional data sources

RESEARCH AND DEVELOPMENT

 


The World Health Organization is gathering the latest scientific findings and knowledge on coronavirus disease (COVID-19) and compiling it in a database. It’s updated daily, downloadable and searchable with filters. It is organized in 5 main areas:
 - Update on research activities for novel coronavirus, which links to the R&D Blueprint page on COVID-19 providing information on research activity and prioritization of R&D, including a Research Roadmap.
 - International Clinical Trial Registry Platform, which allows downloading a file with all COVID-19 trials from the WHO ICTRP database.
 - COVID-19 Emergency Use Listing Procedure (EUL), provides information regarding WHO prequalification of in vitro diagnostics to detect SARS-CoV-2 and a list of products eligible for procurement.
 - Solidarity Clinical Trial for COVID-19 treatments, with general information on the international clinical trial to help find an effective treatment for COVID-19, launched by the World Health Organization and partners.

- Accelerating a safe and effective COVID-19 vaccine, which includes a landscape of COVID-19 candidate vaccines.

The COVID-19 Data Portal aims to bring together relevant datasets for sharing and analysis in an effort to accelerate coronavirus research. It enables researchers to upload, access and analyse COVID-19 related reference data and specialist datasets as part of the wider European COVID-19 Data Platform.

 

A database by Stanford University with information on cell culture, animal model, and clinical data on compounds with proven or potential anti-coronavirus activity, including targeted antivirals, investigational agents, monoclonal antibodies, interferons, repurposed drugs, and promising leads.

 

Evidence mapping and/or systematic reviews/meta-analysis

 

 

A compilation of contents from the Cochrane Library relating to the COVID-19 pandemic, including: Special Collections, rapid reviews, prioritized updates, COVID-19 Study Register, and other resources.


A curated literature hub from NLM/NIH for tracking up-to-date scientific information about the 2019 novel Coronavirus. It provides centralised access to relevant articles in PubMed organized into 8 themes: general, mechanism, transmission, diagnostics, prevention, case report, forecasting and treatment, which includes treatment strategies, therapeutic procedures, and vaccine development.​​​


Clinical trials


A database tracking by the University of Oxford tracking COVID-19 trials and their results, from a wide array of clinical trial registries (US, China, EU, and country-based)


Updated database by the University of Basel with information about worldwide planned, ongoing, and completed trials on any intervention to treat or prevent SARS-CoV-2-infections.

An open-access platform provided by Inato that gathers all available information regarding global clinical trials for SARS-CoV 2. Clear and easy to navigate, the site aims to help clinicians and global healthcare community access essential and comprehensive COVID-19 trial information and research trends.

 

A resource providing information on all COVID-19 clinical trials at a glance.

This page provides aggregate, updated news on coronavirus and COVID-19 clinical trials. It utilises AI analysis and data visualisation for COVID-19 news and social media, providing updates on the latest clinical trials, with insights into trending topics driving Coronavirus reporting.

Provides information on listed clinical studies related to the coronavirus disease (COVID-19). Also allows to search for U.S. Federally-funded clinical studies related to COVID-19. ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine and gathers information of privately and publicly funded clinical studies conducted around the world.


Treatment, Vaccines, and Diagnostics

 

Live meta-analysis and evidence synthesis of potential therapies for COVID-19, including a summary of preliminary results - a project run by the University Lyon-1 and Hospices Civils de Lyon. 


Artis Ventures compiled a database of diagnostics, treatments and vaccines already approved and under development for COVID-19, providing a snapshot and detailed information on each area.

The New York Times provides an updated list of the most-talked-about treatments for the coronavirus and a summary of the available evidence about their effectiveness.  Treatments are labeled as: "Widely used",  "Promising evidence", "Tentative or

mixed evidence", "Not promising" or "Pseudoscience or fraud".

 

 

GHTC - Global Health Technologies Coalition is tracking research and development (R&D) efforts to combat COVID-19. Resources include a WHO Timeline of R&D Activities, US Government-supported R&D Efforts, CEPI Partnerships for COVID-19 Vaccine Candidates and a tracker of R&D efforts by GHTC members. 

 

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has a dedicated page compiling R&D efforts of biopharmaceutical companies related to COVID-19. It has information on treatment, vaccine and diagnostics already approved or in different stages of development.

 

 

The Milken Institute is tracking the development of treatments and vaccines for COVID-19 (coronavirus). It provides an aggregation of publicly-available information from validated sources, including a product-based perspective in downloadable pdf format.

 

 

BioCentury provides a free information portal containing resources related to COVID-19. It has information on therapies and vaccines in preclinical and clinical development and a COVID-19 trial timeline.

 

COVID-19 Pipeline offers concise overviews and analyses of key research areas, including “Epidemiology and Natural History”, “Molecular Virology”, “Diagnostics and Serology”, “Prevention” and “Treatment” (to be added soon). A collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration, and Treatment Action Group - TAG.

 

 

A weekly updated tracker by the RAPS - Regulatory Affairs Professionals Society providing information on the major vaccine candidates in development for the prevention of COVID-19.

 

 

FIND (Foundation for Innovative Diagnostics) provides a resource centre designed to support policymakers and healthcare providers with up-to-date information on tests and testing for SARS-CoV-2 (the causative agent of COVID-19). It includes information about what is in the pipeline, performance data, diagnostic use, and an interactive testing tracker per country.

 

A database by the Academy of Medical Sciences mapping COVID-19 preclinical drug development research across the UK.

 


Financing and Incentives for R&D

 

A tracker to help funders, policymakers, researchers and others understand the evolving landscape of R&D for COVID-19. The dashboards track funding commitments for basic research and product development R&D, and the current status and makeup of the pipeline of new drugs, vaccines and diagnostics, allowing users to identify the key financial and scientific contributors to the global fight against COVID-19.

 

The media platform Devex developed an interactive tool with global COVID-19 funding data from public, private and philanthropic sectors, including a breakdown by focus areas such as research, vaccine/treatment and manufacturing.

 

 

The Research Investments in Global Health study (RESIN) have put together an analysis of global public and philanthropic R&D investments related to coronavirus research.

 

A UKCDR & GloPID-R database to track newly funded research projects. The aim is to support funders and researchers, by providing an overview of research projects mapped against the priorities identified in the WHO Coordinated Global Research Roadmap: 2019 Novel Coronavirus.

 

 

A tracking tool and interactive map of public funding and tax-payer supported R&D initiatives for COVID-19 at universities and public research institutions. By the Universities Allied for Essential Medicines (UAEM), the Student National Medical Association and the American Medical Student Association.

 

A live blog by Science Business compiling information about R&D what governments, funders, companies, universities, associations and scientists are doing related to COVID-19.

 

 

European Union webpage with supported research and innovation projects and initiatives to tackle the spread of coronavirus and preparedness for other outbreaks.​

 

Contains information about pledges made by countries, international organisations or financial institutions during the pledging event led by the European Commission on May 4, 2020.

 


R&D Partnerships 

 

 

A coalition of R&D organizations founded with the aim to accelerate COVID-19 research in resource-limited settings and promote the greatest possible sharing of research knowledge and data.

 

 

An open science drug discovery partnership launched to develop drugs in anticipation of future viral pandemics.

 

 

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard COVID-19 Therapeutics Accelerator initiative launched to coordinate R&D efforts and remove barriers to drug development and scale-up to address the COVID-19 epidemic.

 

INTELLECTUAL PROPERTY AND ACCESS

 

 

The World Intellectual Property Organization - WIPO page provides information on legislative and regulatory measures and voluntary actions regarding COVID-19.

Licensing and access provisions

 

 

Licensing principles to technologies developed at universities to maximize access to innovations. Initially signed by Harvard University, Massachusetts Institute of Technology and Stanford University, with additional signatories and open for endorsement.

 

Patent information

 

 

MedsPaL provides information on the patent and licensing status of selected medicines in low- and middle-income countries. It includes some of the medicines currently being used and tested for COVID-19, such as remdesivir, lopinavir and ritonavir.

 

 

An open database containing information on patents, scholarly research and biological sequences related to human coronaviruses and COVID-19.

  • American Chemical Society

 

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. A report providing an overview of scientific information on small molecules and biologics targeting coronaviruses which may be applicable to COVID-19, with an emphasis on patents. It includes patent information on therapeutic antibodies, cytokines, and nucleic acid-based therapies as well as vaccines.

 

 

An observatory of patents related to COVID-19 technologies, which includes an “Overview of Patents Deposited with the INPI Describing Diagnostic Methods for Coronavirus and Other Respiratory Viruses (06/04/2020)”, containing patent information in Brazil and corresponding WO.

  • Brazilian Association of the Fine Chemicals Industry, Biotechnology and its Specialties (ABIFINA)

 

ABIFINA conducted two patent landscapes of health technologies related to COVID-19. It contains information about patents and applications in Brazil and corresponding WO, which allows searching for equivalent patents in other countries.

 

 

Moderna's list of selected patents granted in the United States related to the candidate vaccine for COVID-19 mRNA-1273.

International Pool of IPRs and other exclusivity rights

 

 

C-TAP was created to voluntarily share COVID-19 health technology-related knowledge, intellectual property and data, drawing on relevant data from existing mechanisms, such as the Medicines Patent Pool and the UN Technology Bank-hosted Technology Access Partnership. Created by the World Health Organization - WHO following an initial request by Costa Rica.

  • Medicines Patent Pool 

 

The Medicines Patent Pool (MPP) has decided to temporarily expand its mandate to include any health technology that could contribute to the global response to COVID-19. The MPP is a United Nations-backed organisation that negotiates with patent holders for licences on life-saving medicines for low- and middle-income countries. 
 

TRIPS Flexibilities: Compulsory licenses and related legislative developments

 

  • Israel

 

On March 18, the Ministry of Health of Israel issued a compulsory license for the use of lopinavir/ritonavir in the treatment of COVID-19. 
Copy of the official document provided by KEI - Knowledge Ecology International
Unofficial English translation provided by KEI - Knowledge Ecology International

 

  • Chile

 

On March 17, the Chilean parliament approved a resolution (896/2020) declaring that the COVID-19 pandemic justifies the use of compulsory licenses for COVID-19 technologies, which can facilitate the procedure for compulsory licenses to be issued in the country.
Unofficial English translation provided by KEI - Knowledge Ecology International

 

  • Ecuador

 

On March 20, the Committee of Education, Culture and Science and Technology of the National Assembly of Ecuador approved a resolution asking the Minister of Health to issue compulsory licenses on all patents related to COVID-19 technologies, as well as access to test data. 
Unofficial English translation provided by KEI - Knowledge Ecology International

 

  • France

 

On March 23, France passed the Emergency Law No 2020-290 to combat the COVID-19 epidemic, which introduced a new article into the public health code (Article L3131-15) giving extraordinary powers to the Prime Minister including to issue compulsory licences bypassing the general provisions in the Intellectual Property Code.

  • Canada

 

On March 25, Canada approved a change in its IP law to facilitate the process to issue compulsory licenses in the event of a public health crisis. The new provision allows the government to issue a compulsory license and negotiate its terms, including compensation, after. 
 

  • Colombia

 

On March 25, Colombia approved a decree allowing the Ministry of Health to declare of public interest all medicines, medical devices, vaccines and other health technologies related to COVID19. The declaration of public interest is a necessary step prior to the grant of a compulsory license. The decree also the flexibilization of the rules regarding registration and importation of health technologies in the country.
 

  • Germany

 

On March 27, Germany parliament passed a law giving powers to the Ministry of Health to issue compulsory licenses for public health reasons, as previously only the Ministry of Economics was allowed to issue compulsory licenses in the country. 
Information in English available at Kluwer Patent Blog

 

Patent oppositions and revocations

 

  • India

The Cancer Patients Aid Association (CPAA) filed a post-grant opposition (revocation) against the patent granted for the drug remdesivir, being tested for the treatment of COVID-19. The document argues that the patent lacks novelty and inventive step, and therefore should not have been granted.

  • Argentina

Fundacion Grupo Efecto Positivo (GEP) filed two pre-grant patent oppositions in Argentina against patent applications for the drug remdesivir filed by Gilead. GEP has requested that the National Institute of Intellectual Property (INPI) reject the applications arguing that the company tries to claim therapy methods that are not patentable in Argentina or combinations of already known substances lacking novelty.


Companies announcements

 

  • Abbvie

 

Following the compulsory license issued by Israel, AbbVie announced that it will not enforce its exclusivity rights over the drugs lopinavir and ritonavir, not only for its use on COVID-19 but for any use, anywhere in the world. 
Official document: Not available.

The Medicines Patents and Licenses Database (MedsPaL) shows a “Commitment not to enforce LPV/r or Ritonavir patents”.
News report: here and here.

 

  • Gilead

Statement on Request to Rescind Remdesivir Orphan Drug Designation. The company obtained orphan drug designation for remdesivir by the U.S. Food and Drug Administration, which grants a 7-year period of market exclusivity in the country. After intense criticism, Gilead requested to rescind the orphan drug designation. The company still holds patents in many countries for the drug, with grants exclusivity over its production and commercialization.
 

  • Roche

After the European Commission consideration to intervene in Roche due to a lack of capacity to produce enough tests for COVID-19, the company announced it will provide information for the production of a testing solution (lysis buffer) if laboratories ask for it. 

Official document: Not available.

News report: here.

  • Medtronic

The company granted an open global license for the manufacturing of ventilators.

  • Novartis

The company announced that it will make available its intellectual property related to the drug hydroxychloroquine to support broad access to the drug if it is approved for COVID-19.

  • Moderna

The company announced that "while the pandemic continues" it "will not enforce COVID-19 related patents against those making vaccines intended to combat the pandemic" and that the company is willing to license upon request their intellectual property for COVID-19 vaccines for the post-pandemic period. The statement includes a list of selected US patents relevant to the mRNA-1273 vaccine against COVID-19. 

PRICING, PROCUREMENT, DISTRIBUTION AND MANUFACTURING

 

 

Distribution

 

A resource developed by ONE "scoring G20 countries plus the EU and AU, and the companies striking deals for promising vaccine candidates". A summary of each deal is provided. 

 

A resource developed by Sasha Trubetskoy with maps and graphs illustrating COVID-19 vaccine distribution agreements by region/country and candidate. Note that the sources of information are not always provided.

Manufacturing

 

An open source-based map of COVID-19 candidate vaccines and manufacturing capacity. Compiled and maintained by the Third World Network.


Estimation of minimum costs of production of active pharmaceutical ingredients for repurposed drugs being tested against COVID-19. The estimated costs were compared with list prices from a range of countries. 

 


Provides an estimation of the cost of goods and manufacturing of diagnostic test GeneXpert, breaking down in various components including the cost of reagents. This testing platform is also used to detect SARS-CoV-2 and is being sold by the company Cepheid for USD 20

Pricing

The Foundation for Innovative New Diagnostics (FIND) provides information about the prices of the test GeneXpert sold by the company Cepheid. GeneXpert is currently being used for COVID-19 as well.


Procurement

 

MedTech Europe is the European trade association for the medical technology industry including diagnostics, medical devices and digital health. The COVID-19 information hub includes information on a series of topics, including a weekly updated document on COVID-19 Procurement Actions monitoring development from across Europe and WHO on procurement actions and initiatives for medical technologies.


The Global Fund, under WHO leadership, is providing immediate funding of up to US$1 billion to help countries fight COVID-19, mitigate the impacts on lifesaving HIV, TB and malaria programs, and prevent fragile health systems from being overwhelmed, through grant flexibilities and the COVID-19 Response Mechanism.

 

 
 
 

 

ABOUT US

 

The Knowledge Network on Innovation and Access to Medicines is a project of the Global Health Centre at the Graduate Institute, Geneva. The project seeks to maximize the contributions of research and analysis to producing public health needs-driven innovation and globally-equitable access to medicines.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.